Site icon pharmaceutical daily

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2022 and recent updates.

Third Quarter Fiscal Year 2022 and Subsequent Highlights:

Management Commentary

“We are pleased to announce that Part A of our ongoing Phase 2 proof-of-concept clinical trial is now fully enrolled, keeping us on-track to release top line data before the end of this current quarter,” stated Simon Allen, Chief Executive Officer of Anebulo. “We look forward to announcing the Part A data and providing further guidance on our path to product approval.”

Third Quarter Fiscal 2022 Financial Results

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo Pharmaceutical’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Anebulo Pharmaceuticals, Inc.

Condensed Balance Sheet Data

 

 

March 31, 2022

 

 

June 30, 2021

 

Assets

 

 

 

 

 

 

 

 

Cash

 

$

16,547,727

 

 

$

19,985,645

 

Total assets

 

$

17,248,467

 

 

$

21,653,491

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Total liabilities

 

 

85,777

 

 

 

241,633

 

Total stockholders’ equity

 

 

17,162,690

 

 

 

21,411,858

 

Total liabilities and stockholders’ equity

 

$

17,248,467

 

 

$

21,653,491

 

Anebulo Pharmaceuticals, Inc.

Condensed Statements of Operations

 

 

Three Months Ended

March 31,

 

 

 

2022

 

 

2021

 

Research and development

 

$

915,363

 

 

$

273,038

 

General and administrative

 

 

964,281

 

 

 

279,093

 

Total operating expenses

 

 

1,879,644

 

 

 

552,131

 

Loss from operations

 

 

(1,879,644

)

 

 

(552,131

)

 

 

 

 

 

 

 

 

 

Other income (expenses), net

 

 

3,153

 

 

(3,701

)

Net loss

 

$

(1,876,491

)

 

$

(555,832

)

Deemed dividends

 

 

 

 

 

(8,208,393

)

Net loss attributable to common stockholders

 

 

(1,876,491

)

 

 

(8,764,225

)

Weighted average common shares outstanding, basic and diluted

 

 

23,344,567

 

 

 

12,982,500

 

Net loss per share, basic and diluted

 

$

(0.08

)

 

$

(0.68

)

 

Contacts

Anebulo Pharmaceuticals, Inc.
Scott Anderson

Head of Investor Relations and Public Relations

(858) 229-7063

scott@anebulo.com

Rex Merchant

Chief Financial Officer

(512) 598-0931

IR@anebulo.com

Exit mobile version